Chairman Mandate 2018
The chairman of the Board of Directors of Prometic Life Sciences Inc. chairs the meetings of the Board and ...
Other content in this Stream
Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on long fibrosis at the 2019 ATS conference
Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.
Prometic announces terms of equity rights offering
Prometic is pleased to confirm the terms of its previously announced equity rights offering for gross proceeds of up to $75,000,000.
Prometic reports its 2019 first quarter financial results
We made excellent progress during the quarter towards completing the necessary development work to permit re-filing of our Ryplazim™ (plasminogen) (“RyplazimTM ”) BLA before the end of 2019
Prometic strengthens its leadership with a new management structure and the appointment of three new directors
Prometic is pleased to announce today a new management structure to provide leadership to the Corporation and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board.
Annual Report 2018
2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.
Quarterly Report 2018 Q3
Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.
Quarterly Report Q2 2018
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).
Corporate Governance and Nominating Committee Charter 2017
The Board of Directors of Prometic Life Sciences Inc. is ultimately responsible for the stewardship of the Corporation which means that it oversees the direction of the Corporation.
Board of Directors Charter 2017
Audit, Risk and Finance Committee Charter 2017
The Committee is mainly responsible for the corporation's financial reporting process, process to identify & manage risks, internal & external audit process, communication systems & capital structure.
Chairman Mandate 2018
The chairman of the Board of Directors of Prometic Life Sciences Inc. chairs the meetings of the Board and assures its good functioning and the good functioning of the committees of the Board.
Virtual Tour of Prometic Life Science's Manufacturing Process
You will discover how our industry leading technology is now being used to extract and purify therapeutic proteins from human plasma to provide for the development of best in class products.
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment